BioPharmSignal logoBioPharmSignal

Biotech News

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

Twist Bioscience Corporation (TWST)Twist Bioscience CorporationCompany update

Antibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 16, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement

Related news

TWSTTwist Bioscience Corporation2026-02-17 12:00 EST

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

TWSTTwist Bioscience Corporation2026-09-09 12:00 EST

Twist Bioscience to Present at Baird 2026 Global Healthcare Conference

View all latest news

Twist Bioscience Corporation

Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows. Oligos and Genes Core products include oligonucleotides, genes and complex DNA constructs used by...

Recent company news

TWSTTwist Bioscience Corporation2026-09-16 12:00 EST

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

TWSTTwist Bioscience Corporation2026-09-09 12:00 EST

Twist Bioscience to Present at Baird 2026 Global Healthcare Conference

TWSTTwist Bioscience Corporation2026-08-05 03:45 EST

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

TWSTTwist Bioscience Corporation2026-08-04 20:01 EST

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

TWSTTwist Bioscience Corporation2026-08-04 12:00 EST

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
188.05 USD
Market cap
4.37B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States